十一月 2025
- Home
- Oy Medix Biochemica Ab
十一月 2025的Oy Medix Biochemica Ab市场份额分析
This Human Rights policy describes Medix Biochemica’s role, objectives and responsibilities in respect of our human rights commitment. We expect our employees, suppliers, distributors, and other business partners whose actions and omissions may directly impact our operations, products or services, to respect human rights and not limit or infringe upon them.
Oy Medix Biochemica Ab(包含公司地区分支机构)
查看更多网站流量和参与度信息- medixbiochemica.com
Oy Medix Biochemica Ab收入截至 十一月 2025为 50M - 75M
Oy Medix Biochemica Ab主要域名产生的收入
3 年中Oy Medix Biochemica Ab主要域名的收入
Oy Medix Biochemica Ab主要域名的收入
Oy Medix Biochemica Ab热门域名的总访问量
了解Oy Medix Biochemica Ab市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Oy Medix Biochemica Ab热门域名的平均访问时长
分析Oy Medix Biochemica Ab参与度指标。
过去 3 个月的平均访问时长
子公司明细
Oy Medix Biochemica Ab热门域名的平均页面浏览量
了解Oy Medix Biochemica Ab如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Oy Medix Biochemica Ab 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Medix Biochemica USA Inc. hired Aydin Parast as Chief Commercial Officer for North America and Europe on Jul 1st '25.Medix Biochemica USA Inc. is pleased to announce that Aydin Parast will be joining Medix Biochemica in late July 2025 as its new Chief Commercial Officer for North America and Europe.
七月 21, 2025阅读更多
新闻Medix Biochemica USA Inc. hires Petra Furu as Vice President of Immunoassay Business Unit.Medix Biochemica welcomes Petra Furu as Vice President of Immunoassay Business Unit.
七月 17, 2025阅读更多
新闻Medix Biochemica USA Inc. acquired CANDOR Bioscience GmbH on Jan 22nd '25.22 January 2025, Espoo, Finland - Medix Biochemica, a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, announced the acquisition of CANDOR Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions.
一月 22, 2025阅读更多
查看 Oy Medix Biochemica Ab 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。